Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to give written consent to participate and agree to have their personal health information shared as required by the study.
- People who are 18 years of age or older at the time of giving consent.
- People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scale called the ECOG scale (scores 0–2, meaning fully active to limited in strenuous activity but able to care for oneself).
- People who have been diagnosed with Stage IIIB, IIIC, or Stage IV Non-Small Cell Lung Cancer (a type of lung cancer) that has not been treated before and cannot be treated with the aim of curing it.
- People whose cancer can be measured on scans according to standard criteria (called RECIST v1.1), with those measurements taken within 28 days before starting treatment.
- People whose cancer has a specific genetic change called a KRAS G12C mutation, confirmed by laboratory testing of tumour tissue or a blood-based test, carried out in a certified laboratory.
- People whose cancer has been tested and shows a PD-L1 score (a marker measured on tumour cells) of between 1% and 49%, confirmed by a certified laboratory.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a serious existing medical condition that the investigating doctor believes would make participation unsafe, including conditions such as interstitial lung disease (scarring or inflammation in the lungs), severe difficulty breathing at rest, or uncontrolled fluid build-up around the heart or lungs.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shetal A Patel, MD, PhD, UNC Lineberger Comprehensive Cancer Center
Phone: 919-984-0000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.